Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport

被引:67
作者
Handelsman, DJ [1 ]
机构
[1] Univ Sydney, Concord Hosp, ANZAC Res Inst, Dept Androl, Sydney, NSW 2139, Australia
关键词
D O I
10.1210/jc.2005-2569
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: The objective of the study was to review the rationale underlying the banning of human chorionic gonadotropin (hCG) and estrogen blockers (antiestrogens, specific estrogen receptor modulators, aromatase inhibitors) in sports for male and female athletes in the light of gender differences in regulation of reproductive physiology. Evidence Acquisition: We reviewed well-controlled clinical studies of exogenous testosterone effects on human muscle size and strength in men and all available evidence relevant to the effects of hCG and estrogen blockers on blood testosterone in men and women. Evidence Synthesis: Well-designed placebo-controlled clinical studies in men with suppressed pituitary-testicular axis establish a strong case that, across a wide range from sub-to supraphysiological doses, muscle growth and strength is proportional to exogenous testosterone dose and resulting blood testosterone concentrations. In men, there is unequivocal evidence that hCG and estrogen blockers cause consistent and sustained rise in blood testosterone concentrations. In women, although there has been no direct testing of ergogenic or myotrophic properties of exogenous testosterone in healthy women, either hCG or estrogen blockers do not produce any consistent or biologically significant increase blood testosterone concentrations. Conclusions: In men undergoing potential stimulation of endogenous blood testosterone concentrations, blood testosterone concentration is a reasonable surrogate measure for muscle growth and increased strength in men. Because hCG and estrogen blockers produce marked increase in blood testosterone concentration in men, this provides strong evidence to support the banning of hCG and estrogen blockers in men. In women, however, the negligible effect on blood testosterone suggests that drug-induced performance enhancement by hCG or estrogen blockers is highly unlikely. Furthermore, routine urinary hCG testing in young women risks invasion of privacy by detecting unrecognized pregnancy. These considerations suggest that prohibition of hCG and estrogen blockers should be restricted to men in which they are well justified.
引用
收藏
页码:1646 / 1653
页数:8
相关论文
共 102 条
  • [1] THE USE OF TESTOSTERONE IN THE TREATMENT OF DEPRESSIONS
    ALTSCHULE, MD
    TILLOTSON, KJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1948, 239 (27) : 1036 - 1038
  • [2] Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients
    Bajetta, E
    Zilembo, N
    Dowsett, M
    Guillevin, L
    Di Leo, A
    Celio, L
    Martinetti, A
    Marchianò, A
    Pozzi, P
    Stani, S
    Bichisao, E
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (02) : 208 - 213
  • [3] What is polycystic ovary syndrome? Are national views important?
    Balen, A
    Michelmore, K
    [J]. HUMAN REPRODUCTION, 2002, 17 (09) : 2219 - 2227
  • [4] Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle
    Bhasin, S
    Woodhouse, L
    Casaburi, R
    Singh, AB
    Mac, RP
    Lee, M
    Yarasheski, KE
    Sinha-Hikim, I
    Dzekov, C
    Dzekov, J
    Magliano, L
    Storer, TW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (02) : 678 - 688
  • [5] The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
    Bhasin, S
    Storer, TW
    Berman, N
    Callegari, C
    Clevenger, B
    Phillips, J
    Bunnell, TJ
    Tricker, R
    Shirazi, A
    Casaburi, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) : 1 - 7
  • [6] Testosterone dose-response relationships in healthy young men
    Bhasin, S
    Woodhouse, L
    Casaburi, R
    Singh, AB
    Bhasin, D
    Berman, N
    Chen, XH
    Yarasheski, KE
    Magliano, L
    Dzekov, C
    Dzekov, J
    Bross, R
    Phillips, J
    Sinha-Hikim, I
    Shen, RQ
    Storer, TW
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 281 (06): : E1172 - E1181
  • [7] Testosterone replacement increases fat-free mass and muscle size in hypogonadal men
    Bhasin, S
    Storer, TW
    Berman, N
    Yarasheski, KE
    Clevenger, B
    Phillips, J
    Lee, WP
    Bunnell, TJ
    Casaburi, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) : 407 - 413
  • [8] Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites
    Birken, S
    Berger, P
    Bidart, JM
    Weber, M
    Bristow, A
    Norman, RJ
    Sturgeon, C
    Stenman, UH
    [J]. CLINICAL CHEMISTRY, 2003, 49 (01) : 144 - 154
  • [9] Use of micro-dose human chorionic gonadotropin (hCG) after clomiphene citrate (CC) to complete folliculogenesis in previous CC-resistant anovulation
    Branigan, EF
    Estes, A
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 192 (06) : 1890 - 1894
  • [10] Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women - A randomized, placebo-controlled trial
    Braunstein, GD
    Sundwall, DA
    Katz, M
    Shifren, JL
    Buster, JE
    Simon, JA
    Bachman, G
    Aguirre, OA
    Lucas, JD
    Rodenberg, C
    Buch, A
    Watts, NB
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (14) : 1582 - 1589